Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 19885836)

1.

Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.

Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, Lenihan DJ, Fan D, Patel SR, Benjamin RS, Khakoo AY.

Cancer. 2010 Jan 1;116(1):184-92. doi: 10.1002/cncr.24683.

2.

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity.

Marslin G, Revina AM, Khandelwal VK, Balakumar K, Prakash J, Franklin G, Sheeba CJ.

Int J Nanomedicine. 2015 Apr 24;10:3163-70. doi: 10.2147/IJN.S75962. eCollection 2015.

3.

[Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].

Nelson-Veniard M, Thambo JB.

Bull Cancer. 2015 Apr 29. pii: S0007-4551(15)00135-6. doi: 10.1016/j.bulcan.2015.03.014. [Epub ahead of print] Review. French.

PMID:
25935231
4.

Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management.

Kim KW, Shinagare AB, Krajewski KM, Pyo J, Tirumani SH, Jagannathan JP, Ramaiya NH.

Korean J Radiol. 2015 Mar-Apr;16(2):304-13. doi: 10.3348/kjr.2015.16.2.304. Epub 2015 Feb 27.

5.

Lichenoid drug eruption due to imatinib mesylate.

Bhatia A, Kanish B, Chaudhary P.

Int J Appl Basic Med Res. 2015 Jan-Apr;5(1):68-9. doi: 10.4103/2229-516X.149253.

6.

Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.

Cheng CT, Tsai CY, Yeh CN, Chiang KC, Chen YY, Wang SY, Chen TW, Tseng JH, Jung SM, Chen TC, Yeh TS.

Anticancer Res. 2014 Nov;34(11):6617-25.

PMID:
25368266
7.

microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.

Akçakaya P, Caramuta S, Åhlen J, Ghaderi M, Berglund E, Östman A, Bränström R, Larsson C, Lui WO.

Br J Cancer. 2014 Nov 25;111(11):2091-102. doi: 10.1038/bjc.2014.548. Epub 2014 Oct 30.

8.

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.

Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.

Anticancer Res. 2014 Sep;34(9):5029-36.

PMID:
25202087
9.

Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.

Pessetto ZY, Ma Y, Hirst JJ, von Mehren M, Weir SJ, Godwin AK.

Mol Cancer Ther. 2014 Oct;13(10):2276-87. doi: 10.1158/1535-7163.MCT-14-0043. Epub 2014 Aug 13.

PMID:
25122069
10.
11.

Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.

Durosinmi MA, Salawu L, Lawal OO, Ojo OS, Alatishe OI, Oyekunle AA, Bolarinwa RA, Adisa AO, Badmos K, Anomneze EE, Ayansanwo AO.

Afr J Med Med Sci. 2013 Dec;42(4):325-32.

PMID:
24839736
12.

Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.

Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ.

Eur J Cancer. 2014 Jul;50(10):1772-8. doi: 10.1016/j.ejca.2014.03.280. Epub 2014 Apr 22.

PMID:
24768330
13.

microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.

Fan R, Zhong J, Zheng S, Wang Z, Xu Y, Li S, Zhou J, Yuan F.

Clin Exp Med. 2015 May;15(2):137-44. doi: 10.1007/s10238-014-0280-y. Epub 2014 Apr 5.

PMID:
24706111
14.

Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report.

Rediti M, Pellegrini E, Molinara E, Cerullo C, Fonte C, Lunghi A, Iori A, Neri B.

Anticancer Res. 2014 Feb;34(2):905-7.

PMID:
24511030
15.

Ageing is a risk factor in imatinib mesylate cardiotoxicity.

Maharsy W, Aries A, Mansour O, Komati H, Nemer M.

Eur J Heart Fail. 2014 Apr;16(4):367-76.

16.

[A case of rectal gastrointestinal stromal tumor in an elderly patient who was successfully treated with imatinib mesylate with no significant adverse events].

Gomi K, Mihara M, Abe M, Ikeda Y, Shimada K, Maruyama K, Kajikawa S, Shirota H.

Gan To Kagaku Ryoho. 2014 Jan;41(1):103-6. Japanese.

PMID:
24423962
17.

[Clinical experience of imatinib mesylate for metastatic or recurrent gastrointestinal stromal tumor].

Toyokawa T, Yamashita Y, Yamamoto A, Shimizu S, Inoue T, Kanazawa A, Tsukamoto T, Ikehara T, Nishiguchi Y.

Gan To Kagaku Ryoho. 2014 Jan;41(1):55-8. Japanese.

PMID:
24423952
18.

Hair graying and loss induced by imatinib mesylate.

Yun SK, Song KH, Hwang SR, Kim HU, Lee NR, Park J.

J Dermatol. 2014 Jan;41(1):107-8. doi: 10.1111/1346-8138.12342. Epub 2013 Dec 20. No abstract available.

PMID:
24354806
19.

Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.

Le Cesne A, Blay JY, Reichardt P, Joensuu H.

Oncologist. 2013;18(11):1192-9. doi: 10.1634/theoncologist.2012-0361. Epub 2013 Oct 17. Review.

20.

Neoodjuvant imatinib mesylate for advanced primary and metastactic/recurrent gastro-intestinal stromal tumour (GIST).

Das D, Ganguly S, Deb AR, Aich RK.

J Indian Med Assoc. 2013 Jan;111(1):21-3.

PMID:
24000503
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk